NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy

NewBiologix and Synastra have announced a collaboration to advance recombinant adeno-associated virus (rAAV) manufacturing for Duchenne gene therapy. The partnership brings together Synastra's expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix's proprietary cell engineering and rAAV manufacturing technologies, aiming to improve the production and scalability of gene therapies for Duchenne muscular dystrophy.